|
 |
Late Stage Drug Development World 2009 |
|
|
1-4 December 2009
London, UK
Late stage drug development is growing at around 20% annually, exceeding the growth rate of Phase II and III Trials. In excess of $12 billion is currently being spent on Phase IIIb/IV studies as public concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency. As a result, Health Network Communications is delighted to announce the first ever strategic forum addressing the major challenges in conducting strategic and compliant late stage studies.
The Bloomsbury Hotel, London, United Kingdom
www.healthnetworkcommunications.com/2009/LSDD
Tel: +44 (0) 207 608 7055
Fax: +44 (0) 207 608 7050
Email: jphillips@healthnetworkcommunications.com |
|
|
|
|
|
|
|
 |
Industry Events |
 |
CPhI Worldwide
5-7 October 2010, Paris, France
CPhI Worldwide was launched in 1990 as an international convention on pharmaceutical ingredients and intermediates. This inaugural CPhI attracted 250 visitors for the 16 exhibitors. Today this has grown to an unrivalled 25,000 industry professionals visiting some 1,430 exhibiting companies from over 125 countries. CPhI is the leading exhibition on pharmaceutical ingredients and allied industries. Each year the exhibition grows larger with exhibitors and visitors conducting significant levels of business at CPhI.
More info >> |
|
 |
News and Press Releases |
 |
Cell Culture Service
The availability of cells at all times is a critical bottleneck in drug screening campaigns. Assay-ready frozen cells therefore have become a valid alter-native to cells from a continuous growing culture in order to avoid this bottleneck.
More info >> |
|
|
